Literature DB >> 16943254

The use of the isolated mouse whole bladder for investigating bladder overactivity.

Adebola C Fabiyi1, Alison F Brading.   

Abstract

The isolated mouse whole bladder was used to study in vitro bladder overactivity evoked by intramural nerve sensitization with bradykinin, mimicking neurogenic bladder overactivity secondary to bladder inflammation. Intravesical pressure responses to intramural electrical stimulation of intramural nerves were measured under isovolumetric condition. Validation showed that carbachol produced a dose-response curve closely mirroring that observed in the isolated muscle strips and demonstrated the dual nature of electrically evoked neurotransmission, consisting of a cholinergic component largely mediated by M(3) receptors and a purinergic component mediated by P2X receptors. ATP generated a biphasic dose-response curve, suggesting that the P2X receptors may be heterogeneous in distribution. Characterization of bradykinin receptors showed bradykinin to be extremely potent in exciting the bladder, producing a dose-response curve with an EC(50) of 90 nM, and bradykinin also enhanced electrically evoked bladder contractions. These effects were inhibited by the B(2) receptor antagonist HOE 140 (d-Arg(0)-Arg(1)-Pro(2)-Hyp(3)-Gly(4)-Thi(5)-Ser(6)-d-Tic(7)-Oic(8)-Arg(9)) but not the B(1) receptor antagonist desArg(10) HOE 140 (H-d-Arf-Arg-Pro-Hyp-Gly-Thi-Ser-d-Tic-Oic-OH) and were also modulated by alpha,beta,methyleneATP. The isolated mouse whole bladder has proved a viable, robust model in which to demonstrate the pharmacological characteristic of the bladder and adds to the repertoire of in vitro tools for investigating potential therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943254     DOI: 10.1124/jpet.106.108902

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 2.  Excitability and contractility in arterioles and venules from the urinary bladder.

Authors:  Nathan R Tykocki; Frederick C Monson
Journal:  Curr Top Membr       Date:  2020-02-17       Impact factor: 3.049

Review 3.  Neuropeptides in lower urinary tract function.

Authors:  Lauren Arms; Margaret A Vizzard
Journal:  Handb Exp Pharmacol       Date:  2011

4.  Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts.

Authors:  Michael B Hovater; Dragos Olteanu; Elisabeth A Welty; Erik M Schwiebert
Journal:  Purinergic Signal       Date:  2008-04-26       Impact factor: 3.765

Review 5.  Purinergic signalling in the urinary tract in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

Review 6.  Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review.

Authors:  Emilio Sacco; Riccardo Bientinesi; Pierfrancesco Bassi; Diego Currò
Journal:  Int Urogynecol J       Date:  2016-02-17       Impact factor: 2.894

7.  The validation of a functional, isolated pig bladder model for physiological experimentation.

Authors:  Brian A Parsons; Marcus J Drake; Andrew Gammie; Christopher H Fry; Bahareh Vahabi
Journal:  Front Pharmacol       Date:  2012-03-30       Impact factor: 5.810

8.  Optogenetic Modulation of Urinary Bladder Contraction for Lower Urinary Tract Dysfunction.

Authors:  Jae Hong Park; Jin Ki Hong; Ja Yun Jang; Jieun An; Kyu-Sung Lee; Tong Mook Kang; Hyun Joon Shin; Jun-Kyo Francis Suh
Journal:  Sci Rep       Date:  2017-01-18       Impact factor: 4.379

9.  Signaling Pathways Mediating Bradykinin-Induced Contraction in Murine and Human Detrusor Muscle.

Authors:  Kinga Borsodi; Helga Balla; Péter József Molnár; Ádám Lénárt; István Kenessey; András Horváth; Attila Keszthelyi; Miklós Romics; Attila Majoros; Péter Nyirády; Stefan Offermanns; Zoltán Benyó
Journal:  Front Med (Lausanne)       Date:  2022-01-20

10.  Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.

Authors:  Tondalaya Gamble; Peter Sand
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.